STOCK TITAN

Tenaya Therapeutics (TNYA) Files Rule 144 Notice for 14,533 Shares

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Tenaya Therapeutics, Inc. (TNYA) filed a Form 144 reporting a proposed sale of 14,533 shares of its common stock through Morgan Stanley Smith Barney, with an aggregate market value of $18,209.85. The filing lists the Nasdaq Global Select Market as the intended exchange and an approximate sale date of 08/18/2025.

The securities were acquired on 08/18/2025 as Restricted Stock Units from the issuer (total RSUs shown: 39,687), with payment listed as N/A. The filing states there were 162,976,102 shares outstanding and reports "Nothing to Report" for securities sold by the reporting person in the past three months. The notice includes the required representation that the signer is unaware of undisclosed material adverse information about the issuer.

Positive

  • Planned sale is small relative to total shares outstanding (14,533 vs. 162,976,102), suggesting limited market impact
  • Brokered transaction through Morgan Stanley Smith Barney, indicating use of an established brokerage channel
  • No reported sales in the prior three months, simplifying aggregation and compliance reporting

Negative

  • None.

Insights

TL;DR: Routine Rule 144 notice for a small proposed sale; appears non-material relative to total outstanding shares.

The Form 144 documents an intended brokered sale of 14,533 common shares valued at $18,209.85, to occur on 08/18/2025. Given total shares outstanding of 162,976,102, the position represents a vanishingly small fraction of equity, which implies limited direct market impact. The securities were recorded as acquired via Restricted Stock Units from the issuer on the same date indicated, and there are no reported sales in the prior three months. This filing follows Rule 144 disclosure processes and contains the standard representation regarding material non-public information.

TL;DR: Administrative insider liquidity disclosure consistent with compliance; no governance red flags disclosed.

The notice identifies the sale channel (Morgan Stanley Smith Barney) and includes the signature representation required by the form. The filing does not disclose any unusual terms, related-party transactions, or prior sales in the three-month lookback. From a governance perspective, this is a standard compliance filing documenting an insider or affiliated person's planned disposition of shares received as RSUs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What does Tenaya Therapeutics' (TNYA) Form 144 report?

The filing reports a proposed sale of 14,533 shares of common stock via Morgan Stanley Smith Barney with an aggregate market value of $18,209.85, approximate sale date 08/18/2025.

How were the shares being sold acquired according to the Form 144?

The shares were acquired on 08/18/2025 as Restricted Stock Units (RSUs) from the issuer; the record shows 39,687 RSUs associated with the account.

Does the Form 144 show any sales by the reporting person in the past three months?

No. The filing states "Nothing to Report" for securities sold by the person in the past three months.

What exchange is the proposed sale expected to occur on?

The filing identifies the Nasdaq Global Select market as the exchange where the sale is to be executed.

Is there any indication of undisclosed material information in the filing?

The signer represents they do not know of any material adverse information about the issuer that has not been publicly disclosed, per the Form 144 representation.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature